Primary Sclerosing Cholangitis clinical trials at University of California Health
6 in progress, 4 open to eligible people
A Study of Experimental PLN-74809 in Cholangitis and Suspected Liver Fibrosis
open to eligible people ages 18-75
A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis
at UC Davis
A Study of Experimental Sulfasalazine for Primary Sclerosing Cholangitis (inflammation and scarring of the bile ducts)
“This research study hopes to find out if experimental treatment with sulfasalazine can help people with PSC.”
open to eligible people ages 15-80
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC.
at UC Davis
A Study of Volixibat to Treat Itching Caused by Primary Sclerosing Cholangitis
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 18 years and up
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
at UC Davis
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
open to eligible people ages 18 years and up
To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of cholangiocarcinoma in patients diagnosed with primary sclerosing cholangitis (PSC).
at UC Davis
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
Sorry, in progress, not accepting new patients
The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.
at UCSF
Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis
Sorry, in progress, not accepting new patients
The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
at UC Davis UCSF
Last updated: